Clinical Trial Search

Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants

Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…

Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants

Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants

Primary: Depressive Symptoms (Measured With an Abbreviated 10-item CES-D) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months…

Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months

Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants

Primary: Number Participants With Neutropenia, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4.03 — 2…

Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants

Primary: Clinical Response (Complete or Partial Response) Rate (Cohort A) — 62.9; 74.8; 69.1 percentage of patients

Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants

Primary: Overall Survival — 83; 79; 79 percentage of patients alive

Primary: Number of Subjects That Completed Oral Anastrozole 1mg Daily for Two Weeks in the Interval Between Diagnostic Breast Biopsy and Definitive Breast Surgery — 10 participants

Primary: Number of Patients With Pathological Complete Response — 2 participants

Primary: Percentage of Participants With Adequate Estrogen Suppression After 8 Weeks of Adjuvant Anastrozole 10 mg Daily — 76.0 percentage of participants

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants

Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants

Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011

Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants

Primary: Number of Participants With Complete Pathologic Response Rate to Pre-operative Treatment in Arm A (Docetaxel for 4 Cycles Followed by Capecitabine for 4 Cycles) or Arm B…

Primary: Rate of Pathologic Complete Response in the Affected Breast After Protocol Therapy — 39 percentage of tumors

Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants

Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33

Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07

Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change

Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months

Primary: Change in Ki-67 in Breast Tissue of High-Risk Women

Primary: Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and…

Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants